Herd immunity by mass vaccination offers the potential to substantially limit the continuing spread of COVID-19, but high levels of vaccine hesitancy threaten this goal. In a cross-country analysis of vaccine hesitant respondents across Latin America in January 2021, we experimentally tested how fiv...e features of mass vaccination campaigns—the vaccine’s producer, efficacy, endorser, distributor, and current population uptake rate—shifted willingness to take a COVID-19 vaccine. We find that citizens preferred Western-produced vaccines, but were highly influenced by factual information about vaccine efficacy. Vaccine hesitant individuals were more responsive to vaccine messengers with medical expertise than political, religious, or media elite endorsements. Citizen trust in foreign governments, domestic leaders, and state institutions moderated the effects of the campaign features on vaccine acceptance. These findings can help inform the design of unfolding mass inoculation campaigns.
more
La mise à disposition des vaccins, des tests et des médicaments disponibles peut prendre longtemps, même en cas d’urgence sanitaire comme la COVID-19. En vue de garantir à tous un accès rapide à ces produits, l’OMS a mis au point un protocole d’utilisation d’urgence, le protocole EUL. ...Son fonctionnement est présenté ici.
more
As of January 20, 2021 the Covid-19 - living NMA initiative collected 150 RCTs and 36 non-randomised studies of vaccines from the ICTRP. 93 of these trials are recruiting patients.
Every country has been affected by COVID-19, with nearly a quarter
of a billion cases and almost 5 million deaths reported globally as of
end of September 2021. Despite the stunning speed with which highly
effective and safe vaccines have been developed, new waves of disease
are still pushin...g health systems to the breaking point, increasingly
transmissible variants are emerging, some survivors are suffering
serious long-term sequelae, and the International Monetary Fund
estimates that global economic losses could exceed US$5.3 trillion
by 2026, if COVID-19 becomes endemic.
Although over 6 billion doses of COVID-19 vaccine have already been
administered, and global production is now reaching 1.5 billion doses
per month, the world is not positioned to end the pandemic. In areas of
high vaccine coverage, there have been massive reductions in serious
disease, hospitalization and death but, globally, vaccine access is highly
inequitable with coverage ranging from 1% to over 70%, depending
largely on a country’s wealth. Consequently, SARS CoV-2 variants
continue to emerge, causing surges of disease and slowing or even
reversing the reopening of societies and economies.
more
Information about vaccine administration
This guide is intended to support national governments developing their national deployment and vaccination plans (NDVPs) for COVID-19 vaccines by outlining the roles, needs and opportunities for community health workers (CHWs) to contribute. This note builds on and is structured to align with the G...uidance on developing a national deployment and vaccination plan for COVID-19 vaccines. By providing CHW-relevant considerations for the VIRAT Tool, this document aims to support national governments in developing robust NDVPs for introducing COVID-19 vaccine(s) that leverage all the community-based deployment, implementation and monitoring tools at their disposal.
more
Here are resources to help accredited continuing education (CE) providers develop and deliver education about the COVID-19 vaccines. If you have any questions about accreditation requirements or any aspect of accredited education related to these vaccines
March 9, 2021
Here you can find a collection of useful manuals, videos, infographics and resource platforms.
The category "Vaccine hesitancy & myths" will be updated regularly with new documents, videos and information material. Please check this category within the COVID-19
https://medbox.org/fi...lter/602505261716D/toolbox/vaccination-strategy#GO
more
Cet article fait partie d’une série d’explications à propos de la mise au point et de la distribution des vaccins.
COVID Reference 23 May 2021
Im Rahmen des Projektes IQ-COVID der LVG & AFS wurden Kurzvideos in vier Sprachen entwi-ckelt, um die afrikanische Community in Bremen anzusprechen. Es ist auch allgemein verwendbar
This article is part two in a series of explainers on vaccine development and distribution. Part one focused on how vaccines work to protect our bodies from disease-carrying germs. This article focuses on the ingredients in a vaccine and the three clinical trial phases. Part three outlines the nex...t part of the vaccine journey: the steps from completing the clinical trial phases through to distribution
Available in English, French, Spanish, Arabic, Chinese and Russian
more
Empfehlungen des Robert Koch-Instituts für Alten- und Pflegeeinrichtungen und Einrichtungen für Menschen mit Beeinträchtigungen und Behinderungen und für den öffentlichen Gesundheitsdienst
Stand 7.4.2021
Warum die Covid-19 RNA Impfung dein Erbgut nicht verändert und wie genau sie funktioniert. Frisch erklärt von deinem Impf-fluencer.
Produziert im Rahmen der #EUMythBusters.